Zobrazeno 1 - 2
of 2
pro vyhledávání: '"J. L. van Dam"'
Autor:
J. L. van Dam, E. M. M. Verkolf, E. N. Dekker, B. A. Bonsing, S. O. Bratlie, L. A. A. Brosens, O. R. Busch, L. M. J. W. van Driel, C. H. J. van Eijck, S. Feshtali, P. Ghorbani, D. J. A. de Groot, J. W. B. de Groot, B. C. M. Haberkorn, I. H. de Hingh, B. van der Holt, T. M. Karsten, M. B. van der Kolk, K. J. Labori, M. S. L. Liem, O. J. L. Loosveld, I. Q. Molenaar, M. B. Polée, H. C. van Santvoort, J. de Vos – Geelen, M. L. Wumkes, G. van Tienhoven, M. Y. V. Homs, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, for the Dutch Pancreatic Cancer Group
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvan
Externí odkaz:
https://doaj.org/article/9bd0b84a5c244ba18797a99563ce5af4
Autor:
Q. P. Janssen, J. L. van Dam, B. A. Bonsing, H. Bos, K. P. Bosscha, P. P. L. O. Coene, C. H. J. van Eijck, I. H. J. T. de Hingh, T. M. Karsten, M. B. van der Kolk, G. A. Patijn, M. S. L. Liem, H. C. van Santvoort, O. J. L. Loosveld, J. de Vos-Geelen, B. M. Zonderhuis, M. Y. V. Homs, G. van Tienhoven, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, for the Dutch Pancreatic Cancer Group
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are hi
Externí odkaz:
https://doaj.org/article/c4666a70be2f4516b363089ddb9e6b2b